A Novel Risk Stratification Model for Patients with Non-ST Elevation Myocardial Infarction in the Korea Acute Myocardial Infarction Registry (KAMIR): Limitation of the TIMI Risk Scoring System
暂无分享,去创建一个
Ju Han Kim | M. Jeong | Y. Ahn | Young Jo Kim | M. Cho | C. Kim | I. Seong | K. Seung | Seung‐Jung Park | S. Chae
[1] M. Grabowski,et al. Admission B-type natriuretic peptide assessment improves early risk stratification by Killip classes and TIMI risk score in patients with acute ST elevation myocardial infarction treated with primary angioplasty. , 2007, International journal of cardiology.
[2] D. Morrow,et al. Pathophysiology, prognostic significance and clinical utility of B-type natriuretic peptide in acute coronary syndromes. , 2004, Clinica chimica acta; international journal of clinical chemistry.
[3] D. Ardissino,et al. N-Terminal Pro-Brain Natriuretic Peptide on Admission Has Prognostic Value Across the Whole Spectrum of Acute Coronary Syndromes , 2004, Circulation.
[4] Á. Avezum,et al. A validated prediction model for all forms of acute coronary syndrome: estimating the risk of 6-month postdischarge death in an international registry. , 2004, JAMA.
[5] Felix Zijlstra,et al. Prognostic Assessment of Patients With Acute Myocardial Infarction Treated With Primary Angioplasty: Implications for Early Discharge , 2004, Circulation.
[6] F. Botto,et al. Relative value of N-terminal probrain natriuretic peptide, TIMI risk score, ACC/AHA prognostic classification and other risk markers in patients with non-ST-elevation acute coronary syndromes. , 2004, European heart journal.
[7] G. Stone,et al. Predicting mortality in patients with ST-elevation myocardial infarction treated with primary percutaneous coronary intervention (PAMI risk score). , 2004, The American journal of cardiology.
[8] Á. Avezum,et al. Predictors of hospital mortality in the global registry of acute coronary events. , 2003, Archives of internal medicine.
[9] S. Yusuf,et al. Effects of Aspirin Dose When Used Alone or in Combination With Clopidogrel in Patients With Acute Coronary Syndromes: Observations From the Clopidogrel in Unstable angina to prevent Recurrent Events (CURE) Study , 2003, Circulation.
[10] M. Sabatine,et al. Evaluation of B-type natriuretic peptide for risk assessment in unstable angina/non-ST-elevation myocardial infarction: B-type natriuretic peptide and prognosis in TACTICS-TIMI 18. , 2003, Journal of the American College of Cardiology.
[11] J. Herlitz,et al. N-Terminal Pro-B-Type Natriuretic Peptide and Long-Term Mortality in Acute Coronary Syndromes , 2002, Circulation.
[12] S. Yusuf,et al. Benefit of Clopidogrel in Patients With Acute Coronary Syndromes Without ST-Segment Elevation in Various Risk Groups , 2002, Circulation.
[13] E. Antman,et al. Validation of the thrombolysis in myocardial infarction (TIMI) risk score for unstable angina pectoris and non-ST-elevation myocardial infarction in the TIMI III registry. , 2002, The American journal of cardiology.
[14] L. Wallentin,et al. The prognostic and therapeutic implications of increased troponin T levels and ST depression in unstable coronary artery disease: the FRISC II invasive troponin T electrocardiogram substudy. , 2002, American heart journal.
[15] E. Antman,et al. Enoxaparin is superior to unfractionated heparin for preventing clinical events at 1-year follow-up of TIMI 11B and ESSENCE. , 2002, European heart journal.
[16] E. Antman,et al. An integrated clinical approach to predicting the benefit of tirofiban in non-ST elevation acute coronary syndromes. Application of the TIMI Risk Score for UA/NSTEMI in PRISM-PLUS. , 2002, European heart journal.
[17] M. Sabatine,et al. The prognostic value of B-type natriuretic peptide in patients with acute coronary syndromes. , 2001, The New England journal of medicine.
[18] C. Vassanelli,et al. [Comparison of early invasive and conservative strategies in patients with unstable coronary syndromes treated with the glycoprotein IIb/IIIa inhibitor tirofiban]. , 2001, Italian heart journal. Supplement : official journal of the Italian Federation of Cardiology.
[19] J. W. Box,et al. Influence of diabetes mellitus on clinical outcomes across the spectrum of acute coronary syndromes. Findings from the GUSTO-IIb Study , 2000 .
[20] E. Antman,et al. TIMI Risk Score for ST-Elevation Myocardial Infarction: A Convenient, Bedside, Clinical Score for Risk Assessment at Presentation: An Intravenous nPA for Treatment of Infarcting Myocardium Early II Trial Substudy , 2000, Circulation.
[21] S. Yusuf,et al. Impact of Diabetes on Long-Term Prognosis in Patients With Unstable Angina and Non–Q-Wave Myocardial Infarction: Results of the OASIS (Organization to Assess Strategies for Ischemic Syndromes) Registry , 2000, Circulation.
[22] E. Antman,et al. The TIMI risk score for unstable angina/non-ST elevation MI: A method for prognostication and therapeutic decision making. , 2000, JAMA.
[23] C B Granger,et al. Risk stratification and therapeutic decision making in acute coronary syndromes. , 2000, JAMA.
[24] E W Steyerberg,et al. Predictors of outcome in patients with acute coronary syndromes without persistent ST-segment elevation. Results from an international trial of 9461 patients. The PURSUIT Investigators. , 2000, Circulation.
[25] F. Ragmin. Invasive compared with non-invasive treatment in unstable coronary-artery disease: FRISC II prospective randomised multicentre study , 1999, The Lancet.
[26] R. Califf,et al. Low-molecular-weight heparins in non-ST-segment elevation ischemia: the ESSENCE trial. Efficacy and Safety of Subcutaneous Enoxaparin versus intravenous unfractionated heparin, in non-Q-wave Coronary Events. , 1998, The American journal of cardiology.
[27] R. Califf,et al. Low-molecular-weight heparins in non–ST-segment elevation ischemia: the ESSENCE trial , 1998 .
[28] J Col,et al. Predictors of 30-day mortality in the era of reperfusion for acute myocardial infarction. Results from an international trial of 41,021 patients. GUSTO-I Investigators. , 1995, Circulation.
[29] J. Herlitz,et al. N-Terminal ProB – Type Natriuretic Peptide and Long-Term Mortality in Acute Coronary Syndromes , 2002 .
[30] J. W. Box,et al. Influence of diabetes mellitus on clinical outcomes across the spectrum of acute coronary syndromes. Findings from the GUSTO-IIb study. GUSTO IIb Investigators. , 2000, European heart journal.
[31] L. Wallentin,et al. Invasive compared with non-invasive treatment in unstable coronary-artery disease: FRISC II prospective randomised multicentre study , 1999 .